An Open-Label, Randomized, Single Dose, Five-Period Crossover Study to Evaluate the Relative Bioavailability of Different Formulations of GSK1838262 in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 13 May 2013
At a glance
- Drugs Gabapentin enacarbil (Primary)
- Indications Postherpetic neuralgia; Restless legs syndrome
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 21 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Feb 2009 New trial record